Katherine S. Virgo, PhD
Informed by new clinical evidence, ASCO has issued updated guidance on the use of second-line hormonal therapy for chemotherapy-naïve patients with castration-resistant prostate cancer (CRPC). The provisional clinical opinion (PCO) addresses patients who are asymptomatic, with only biochemical evidence of CRPC, as well as those who have documented metastases and minimal symptoms.
The PCO states that no evidence exists for optimal order of hormonal therapies for CRPC beyond second-line treatment. In addition to the evidence from clinical trials, the expert panel relied on a consensus technique that drew upon clinical experience, training, and judgement “when evidence was limited,” Eric A. Singer, MD, MA, a co-chair of the panel, said in the release. “We hope that this PCO will offer clinicians and patients timely direction to help inform treatment planning and shared decision making."
Virgo KS, Basch E, Loblaw DA, et al. Second-line hormonal therapy for men with chemotherapy-naïve castration-resistant prostate cancer PCO [published online April 25, 2017]. J Clin Oncol. doi:10.1200/JCO.2017.72.8030.
... to read the full story